Literature DB >> 11873939

Neoadjuvant treatment with docetaxel and the effects of irradiation for human ovarian adenocarcinoma and cervical squamous cell carcinoma in vitro.

Shinako Araki1, Yasunari Miyagi, Kunihiro Kawanishi, Junko Yamamoto, Atsushi Hongo, Junichi Kodama, Mitsuo Yoshinouchi, Takafumi Kudo.   

Abstract

The in vitro radiosensitizing effects of docetaxel have been reported, but the DNA damage caused by the irradiation after docetaxel exposure has not been investigated. In this study, the authors attempted to evaluate the radiosensitizing effects in terms of cell survival and DNA single-strand breaks in a human ovarian adenocarcinoma cell line (known as line BG-1) and a human cervical squamous cell carcinoma cell line (known as line SiHa). The cell lines were exposed to various concentrations of docetaxel (from 2.27 x 10(-3) to 2.27 microg/ml) to investigate the cytocidal effects by colony-formation assay. DNA single-strand breaks after exposure to 2.27 microg/ml of docetaxel for 30 min or 100 min were measured by the alkaline-elution assay. The remarkable cytotoxicity of docetaxel followed by irradiation was observed when concentrations were greater than 2.27 x 10(-2) microg/ml in both cell lines. The combination of docetaxel and irradiation appears to be supraadditive. The DNA single-strand breaks induced by the irradiation were enhanced in both cell lines (BG-1; P < 0.01, SiHa; P < 0.05). The synergistic cytocidal effect cannot be explained quantitatively only by the single-strand breaks.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11873939     DOI: 10.18926/AMO/31723

Source DB:  PubMed          Journal:  Acta Med Okayama        ISSN: 0386-300X            Impact factor:   0.892


  1 in total

1.  Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition.

Authors:  Martina Di Modica; Lucia Sfondrini; Viola Regondi; Stefania Varchetta; Barbara Oliviero; Gabriella Mariani; Giulia Valeria Bianchi; Daniele Generali; Andrea Balsari; Tiziana Triulzi; Elda Tagliabue
Journal:  Oncotarget       Date:  2016-01-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.